Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Boehringer Ingelheim
McKesson
Merck
Moodys

Last Updated: November 18, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,514,422

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,514,422
Title:5HT.sub.2c receptor modulators
Abstract: The present invention relates to novel compounds of Formula (I): ##STR00001## which act as 5HT.sub.2C receptor modulators. These compounds are useful in pharmaceutical compositions whose use includes the treatment of obesity.
Inventor(s): Smith; Brian (San Diego, CA), Smith; Jeffrey (San Diego, CA)
Assignee: Arena Pharmaceuticals, Inc. (San Diego, CA)
Application Number:10/917,979
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,514,422
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,514,422

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY   Start Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE   Start Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY TREATING OBESITY   Start Trial
Eisai Inc BELVIQ XR lorcaserin hydrochloride TABLET, EXTENDED RELEASE;ORAL 208524-001 Jul 15, 2016 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY INDUCING SATIETY   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY DECREASING FOOD INTAKE   Start Trial
Eisai Inc BELVIQ lorcaserin hydrochloride TABLET;ORAL 022529-001 Jun 27, 2012 RX Yes Yes   Start Trial   Start Trial METHOD FOR CHRONIC WEIGHT MANAGEMENT BY CONTROLLING WEIGHT GAIN   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,514,422

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 294781   Start Trial
Australia 2003221866   Start Trial
Brazil 0309303   Start Trial
Brazil PI0309303   Start Trial
Canada 2481723   Start Trial
China 100486967   Start Trial
China 101485664   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Johnson and Johnson
Moodys
Baxter
Harvard Business School
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.